BC Innovations | Oct 24, 2017
Distillery Techniques

Disease models

TECHNOLOGY: Cell models A biobank of insertional mutagenesis-derived haploid mouse ESCs could be used to link genes to disease-related phenotypes in homogeneous cell populations. The biobank consists of over 100,000 haploid mouse ESCs with genetically...
BC Extra | Sep 28, 2017
Preclinical News

Researchers report first Haplobank data

In a paper published in Nature , researchers at the Austrian Academy of Sciences and colleagues reported the first data from Haplobank, an open-access haploid mouse embryonic stem cell (ESC) bank created in collaboration with the...
BC Innovations | Jan 18, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Viral infection Cell culture and mouse studies suggest inhibiting PLA2G16 could help treat picornaviral infections. In HeLa cells infected with coxsackievirus, enterovirus, human rhinovirus or other picornaviruses, PLA2G16 knockout decreased infectivity by picornaviruses compared...
BC Innovations | Mar 10, 2016
Distillery Therapeutics

Therapeutics: Lipoprotein-associated phospholipase A2 (PLA2G7; PAFAH; Lp-PLA2)

Ophthalmic disease INDICATION: Diabetic macular edema (DME) In vitro and rat studies identified a PLA2G7 inhibitor that could help treat DME. Chemical synthesis and in vitro studies of pyrimidone analogs identified a compound that inhibited...
BC Innovations | Mar 3, 2016
Emerging Company Profile

SNP it all together

Genomewide association studies can link SNPs to specific disease phenotypes, but the narrow scope of individual SNP studies limits their power of prediction for targeting the associated genes. Genomics plc is developing a computational platform...
BC Innovations | Jan 14, 2016
Distillery Therapeutics

Therapeutics: Phospholipase A2 (PLA2)

Hepatic disease INDICATION: Liver fibrosis; liver disease Mouse studies identified a PLA2 inhibitor that could help treat liver fibrosis and non-alcoholic fatty liver disease (NAFLD). In a mouse model of chemical-induced liver damage, a small...
BC Innovations | Oct 29, 2015
Distillery Therapeutics

Therapeutics: Phospholipase A2 group IID (PLA2G2D)

Infectious disease INDICATION: Respiratory infection; viral infection; SARS-associated coronavirus In vitro and mouse studies suggest inhibiting PLA2G2D in the lungs could help treat viral respiratory infections in elderly patients. Lung levels of the pro-resolving, anti-inflammatory...
BC Week In Review | Oct 12, 2015
Company News

Diadexus, OriGene deal

Diadexus granted OriGene exclusive rights to develop and commercialize Diadexus’ PLAC ELISA test in undisclosed Asian countries. OriGene purchased $1 million in diaDexus stock at about $3.82 per share, which is about a 27% premimum...
BC Innovations | Sep 3, 2015
Targets & Mechanisms

Low-fat brain

While most of the focus in Alzheimer's disease is on slowing or stopping the degeneration of neurons, a team at the University of Montreal has found that one cause of the disease could lie in...
BC Extra | Aug 19, 2015
Financial News

Celsus, Volution raising $75 million

Celsus Therapeutics plc (NASDAQ:CLTX) said that after it reverse-merges with Volution Immuno Pharmaceuticals S.A. (Geneva, Switzerland) it will raise $75 million in a private placement led by Deerfield. Venrock, Vivo Capital, Foresite Capital, New Enterprise...
Items per page:
1 - 10 of 215